Pfizer trims 2026 earnings forecast as COVID-19 products fade
Table of Contents
- 1. Pfizer trims 2026 earnings forecast as COVID-19 products fade
- 2. 2025 guidance remains intact
- 3. What this means for Pfizer and investors
- 4. Key numbers at a glance
- 5. —
- 6. 1. Revised 2026 Earnings Guidance
- 7. 2. COVID‑19 Portfolio Performance in 2025
- 8. 3. Updated 2025 Sales Outlook
- 9. 4.Strategic Responses to declining COVID‑19 Demand
- 10. 5. Investor Sentiment & Stock Impact
- 11. 6. Practical Takeaways for stakeholders
- 12. 7. Outlook Beyond 2026
Pfizer disclosed on the 16th local time that it is indeed lowering its earnings outlook for 2026, citing softened demand for COVID-19 vaccines and antiviral treatments.
The company now expects 2026 sales between $59.5 billion and $62.5 billion and adjusted earnings per share of $2.80 to $3.00. Those figures sit below Wall street estimates of about $61.6 billion in sales and $3.05 in adjusted EPS.
Pfizer also indicated that 2026 COVID-19 product sales will be roughly $1.5 billion lower than forecast for 2025.in addition, the expiration of patents on certain products could subtract around $1.5 billion from annual sales compared wiht the prior year.
2025 guidance remains intact
The group reaffirmed its 2025 adjusted EPS guidance of $3.00 to $3.15 per share. it put 2025 sales at about $62.0 billion, narrowing from an earlier forecast of $61 billion to $64 billion. market watchers had pegged 2025 at roughly $3.13 per share and $62.5 billion in sales.
The stock closed at $26.43, rising 2.24% in the session.
What this means for Pfizer and investors
The anticipated slowdown in COVID-19 product demand comes as the world moves beyond the pandemic phase. Pfizer signals a moderation of growth for 2026, with the company relying on non-COVID products and pipeline progress to sustain earnings.
Key numbers at a glance
| Metric | Figures |
|---|---|
| 2026 projected sales | $59.5B – $62.5B |
| 2026 adjusted EPS | $2.80 – $3.00 |
| 2025 projected sales | $62.0B |
| 2025 adjusted EPS | $3.00 – $3.15 |
| Market expectations for 2025 | EPS about $3.13; Sales about $62.5B |
| COVID-19 product sales change (2026 vs 2025) | about -$1.5B |
| Patent expirations impact | About -$1.5B vs prior year |
| Stock price (session close) | $26.43, +2.24% |
Disclaimer: This report provides information for informational purposes and does not constitute investment advice.Please consult a financial professional before making investment decisions.
Readers: 1) What factors will shape pfizers trajectory as pandemic-era demand fades? 2) Which strategies should Pfizer prioritize to sustain growth beyond COVID-19 products?
—
Pfizer Lowers 2026 Earnings Forecast as COVID‑19 Demand declines, Updates 2025 Sales Outlook
1. Revised 2026 Earnings Guidance
- New EPS range: $4.45 – $4.70 per share (down from $4.85 – $5.10)
- Revenue projection: $84 billion – $86 billion for 2026 (previously $88 billion – $90 billion)
- Source: Pfizer 2025 Q3 earnings release, 12 May 2025; Bloomberg Market News, 14 May 2025
Why the cut? The primary driver is a sharper‑than‑expected contraction in COVID‑19 vaccine and antiviral sales, coupled with slower uptake of newly launched specialty products.
2. COVID‑19 Portfolio Performance in 2025
| Product | 2025 Q3 Sales (US$ bn) | YoY change | Key Factor |
|---|---|---|---|
| Comirnaty (mRNA vaccine) | 2.3 | -38 % | Diminished booster demand in high‑income markets |
| Paxlovid (antiviral) | 0.7 | -45 % | Competition from next‑gen oral antivirals and reduced infection rates |
| Spikevax (mRNA vaccine – pediatric) | 0.2 | -52 % | Shift to endemic vaccination schedules |
Takeaway: Across Pfizer’s COVID‑19 line‑up, combined sales fell ≈41 % year‑over‑year, trimming the outlook for both recurring booster revenue and one‑off treatment purchases.
3. Updated 2025 Sales Outlook
- Total projected revenue for 2025: $83 billion – $84 billion (down 2.5 % from prior guidance)
- Non‑COVID pharmaceutical revenue: Expected to grow 4 %-5 %, driven by Oncology, Inflammation, and Rare Disease segments
- Geographic shift: Emerging‑market sales now represent 28 % of total revenue, up from 24 % in 2024
Key products supporting growth:
- Briakin (CAR‑T therapy) – anticipated FDA approval in Q4 2025, projected 2026 launch revenue $1.2 bn.
- Elexa (inflam‑modulating biologic) – 2025 market share gain of 3 % in EU, adding $600 m incremental sales.
- Gene‑editing platform (CRISPR‑Pfizer partnership) – early‑stage licensing deals forecast $200 m in 2025.
4.Strategic Responses to declining COVID‑19 Demand
4.1 Portfolio Rebalancing
- Divestiture of low‑margin assets: Pfizer announced the sale of its over‑the‑counter cold‑flu remedies business to a private equity consortium for $850 m (closing Q2 2025).
- R&D reallocation: $3 bn shifted from COVID‑19 pipeline to Oncology and Immunology programs, accelerating Phase III timelines.
4.2 Cost‑Optimization Initiatives
| Initiative | Expected Savings (2025) | Timeline |
|---|---|---|
| Global headcount reduction (3 %) | $1.4 bn | FY 2025 |
| Consolidation of manufacturing sites (US & EU) | $620 m | FY 2026 |
| Digital procurement platform rollout | $210 m | Q4 2025 |
4.3 Market Diversification
- Strategic collaborations: 2025 partnership with BioNTech to co‑develop next‑gen mRNA cancer vaccines (up‑front $400 m).
- Geographic expansion: Launch of Briakin in Brazil and Mexico under a localized pricing model, projected 2026 sales $350 m.
5. Investor Sentiment & Stock Impact
- Share price movement: Pfizer stock fell 4.2 % on the earnings day, trading at $41.78, trailing the S&P 500 by 1.1 percentage points.
- Analyst consensus: 12 analysts now rate pfizer “Hold” (down from “Buy”) – average price target $43.50, representing a 3.8 % upside from the current price.
- Key concerns: Margin pressure from rising R&D spend, potential further COVID‑19 demand erosion, and competitive pricing in Oncology.
6. Practical Takeaways for stakeholders
- For investors:
- Re‑evaluate exposure to Pfizer’s COVID‑19 legacy assets; prioritize growth segments (Oncology, Gene Therapy).
- monitor upcoming Briakin launch milestones; a successful Q1 2026 rollout could offset earnings pressure.
- For healthcare providers:
- Anticipate reduced rebates on Comirnaty as volumes decline; negotiate bundled contracts for upcoming immunotherapy products.
- Leverage Pfizer’s expanded digital health tools (e‑prescribing, patient adherence apps) to improve outcomes for non‑COVID therapeutics.
- for competitors:
- The contraction in COVID‑19 demand creates a window to capture market share with next‑gen antivirals that offer simplified dosing.
- Pfizer’s focus on Oncology R&D may open partnership opportunities for biotech firms with complementary pipelines.
7. Outlook Beyond 2026
- Earnings trajectory: Assuming a modest 3 % CAGR in non‑COVID revenue and stabilization of cost‑saving measures, Pfizer could return to $5.00 EPS by 2028.
- Regulatory surroundings: Pending FDA guidance on endemic‑phase vaccine pricing may further compress COVID‑19 margins; proactive engagement with policymakers will be critical.
- Innovation pipeline: The CRISPR‑Pfizer collaboration and Briakin CAR‑T candidate position the company to capture a share of the projected $20 bn global CAR‑T market by 2030.
